Nosopharm is a biotechnology company focused on the discovery and development of innovative anti-infective drugs, particularly targeting antimicrobial resistance and infectious diseases. The company leverages its unique expertise in the exploitation of two underexplored bacteria, Photorhabdus and Xenorhabdus, which are known for their antimicrobial properties. This specialized drug discovery platform allows Nosopharm to identify and develop novel bioactive molecules that can serve as potential treatments for serious infections caused by multidrug-resistant pathogens. Their lead candidate, NOSO-502, represents a new class of antibiotics called Odilorhabdins, specifically designed to combat infections caused by resistant strains of Enterobacteriaceae, including Escherichia coli and Klebsiella pneumoniae.

In addition to NOSO-502, Nosopharm is advancing other research and development programs aimed at addressing the growing threat of antimicrobial resistance. The company is actively exploring the potential of its drug discovery platform to develop treatments for various infectious diseases, including those caused by resistant strains of Pseudomonas aeruginosa and Candida species. By focusing on the unique metabolic capabilities of Photorhabdus and Xenorhabdus, Nosopharm aims to contribute significantly to the global fight against infectious diseases, which remain a major public health challenge. The company is also open to partnerships with industrial and academic entities to further enhance its innovative pipeline.

France

Nosopharm is an innovative biotechnology company headquartered in Lyon (France) and specialized in the research and development of new molecules to combat antimicrobial resistance (AMR).

The mission of Nosopharm is to discover and develop novel first-in-class anti-infectives addressing unmet medical needs.

The innovative anti-infective drug discovery platform developed by Nosopharm is based on the therapeutic exploitation of a very original bioresource: the bacterial genera Xenorhabdus and Photorhabdus.

Nosopharm

Company Details